Log In
BCIQ
Print this Print this
 

RORgamma agonist (LYC-55716)

  Manage Alerts
Collapse Summary General Information
Company Lycera Corp.
DescriptionOral selective RAR-related orphan receptor C (RORC; RORgamma) agonist that enhances effector function of T helper 17 cells and attenuates immunosuppressive mechanisms
Molecular Target RAR-related orphan receptor C (RORC) (RORgamma)
Mechanism of ActionRAR-related orphan receptor (ROR) agonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I/II
Standard IndicationSolid tumors
Indication DetailsTreat advanced, relapsed or refractory solid tumors; Treat solid tumors
Regulatory Designation
PartnerCelgene Corp.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$5.0M


 Deals Details
Get a free BioCentury trial today